Course of serum lipoprotein(a) and acute phase protein levels in patients undergoing open heart surgery

Journal of Cardiovascular Surgery

Volumn 43, Issue 6, 2002, Pages 811-815

  Kaklikkaya, I ^a   Ozdemir R ^a   Orem A ^b   Unal M ^c   Sonmez B ^c   Ozcan F ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b Department of Biochemistry ^*  (Turkey)

^c FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

Author keywords

Acute phase proteins; Cardiopulmonary bypass; Lipoproteins

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; LIPOPROTEIN A; OROSOMUCOID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CARDIOPULMONARY BYPASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER; MALE; OPEN HEART SURGERY; PATHOGENESIS; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PROTEIN SYNTHESIS; STATISTICAL ANALYSIS; THROMBOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL;

ACUTE-PHASE PROTEINS; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; COHORT STUDIES; CORONARY ARTERY BYPASS; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0036928969     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kirklin JW, Barratt-Boyes BG. Cardiac surgery. 2nd edition. New York: Churchill Livingstone Inc., 1993:61-127.
2. Werner M, Cohnen G. Changes in serum proteins in the immediate postoperative period. Clin Sci 1969;36:173-84.
3. Örem A, Deǧer O, Kulan K, Önder E, Kiran E, Uzunosmanoǧlu D. Evaluation of Lipoprotein (a) [Lp(a)] as a risk factor for coronary artery disease in Turkish population. Clin Biochem 1995;28:171-3.
4. Rhads GG, Dahlen G, Berg K, Morten NG, Dannerberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986;256:2540-4.
5. Kawade M, Maeda S, Abe A, Yamashiro M. Alterations in plasma Lp(a) lipoprotein and acute phase proteins after surgical operation. Clin Chem 1984;30:941-3.
6. Sgoutas DS, Lattouf OM, Finlayson DC, Clark RV. Paradoxal response of plasma lipoprotein(a) in patients undergoing cardiopulmonary bypass. Atherosclerosis 1992;97:29-36.
7. Berg K. A new serum type system in man, the Lp system. Acta Pathol Microbiol Scand 1963;59:369-71.
8. Albers JJ, Cabana VG, Warnick GR, Hazzard WR. Lp(a) lipoproteins: Relationship to sinking pre-β lipoprotein, hyperlipoproteinemia and apolipoprotein B. Metabolism 1975;24:1047-54.
9. Thiery J, Armstrong VM, Schleef J, Creutzfeldt C, Creutzfeldt W, Siedel D. Serum lipoprotein Lp(a) concentrations are not influenced by an HMG-CoA reductase inhibitor. Klin Wochenschr 1988;66:462-3.
10. Lippi G, Guidi G. Biochemical risk factors and patient's outcome; the case of lipoprotein(a). Clin Chim Acts 1999;280:59-71.
11. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawede M. Transient changes of serum lipoprotein (a) as an acute phase protein. Atherosclerosis 1998;78:145-50.
12. Örem A, Deǧer O, Çimşit G, Karahan SC, Akyol N, Yildirim S. Plasma lipoprotein(a) and its relationship with disease activity in patient with Behçet's disease. Eur J Clin Chem Clin Biochem 1995;33:473-8.
13. Cobbaert C, Louisa A, Struijk L, Demeyere R, Meyns B. Lipoprotein(a) changes during and after coronary artery bypass grafting: an epiphenomenon? Ann Clin Biochem 1998;35:75-9
14. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V. Lipoprotein(a) and coronary heart disease risk: a nested case control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89:59-67.
15. Farmer JA, Gotto AM, Phill D. Risk factors for coronary artery disease. In: Braunwald E, editor. Heart disease. Philadelphia: WB Saunders Co., 1997:1125-60.
16. Stubbe I, Gustafson A, Nilsson-Ehle P. Alterations in plasma proteins and lipoproteins in acute myocardial infarction: effects of activation of lipoprotein lipase. Scand J Clin Lab Invest 1982;42: 437-44.
17. Finlayson DC, Hunter RL, Check I, Levy JH. Serum protein changes during cardiopulmonary bypass: implications for host defence. Perfusion 1990;5:101-4.
18. Koren E, Armstrong VW, Mueller G, Wilson PR, Schuff Werner P, Thiery J. Apolipoprotein A-I and apolipoprotein B containing lipoprotein particles in coronary patient treated with extracorporial low density lipoprotein precipitation (HELP). Atherosclerosis 1992;95:157-70.
19. Sein EA. Clinical significance and measurement of apolipoprotein A1 and B concentration. In: Wernick GR, editor. Methods for clinical laboratory measurement of lipid and lipoprotein risk factors. Washington: AACC Press, 1991:87-100.
20. Stryer L. Biochemistry. New York: WH Freemann and Co., 1998: 283-314.
21. Merrill EW. Properties of materials affecting the behaviour of blood at their surfaces. N Y Acad Sci 1977;19:6-8.
22. Cushing GL, Gaubatz JW, Nava ML, Bardick BJ, Bacon TM, Guyton JR. Quantitation and localization of apolipoproteins(a) and B in coronary artery bypass vein grafts resected at re-operation. Atheriosclerosis 1989;9:593-603.